America's biopharmaceutical companies are committed to developing solutions to help diagnose, treat and prevent COVID-19, the disease caused by a novel strain of coronavirus called SARS-CoV-2. The virus is a new form of coronavirus and appeared in late 2019. The biopharmaceutical industry is responding rapidly to COVID-19 and has a long track record of developing solutions to combat a range of infectious diseases and bring deep scientific expertise from decades of working with similar viruses such as MERS, SARS and influenza. Over the past several decades, PhRMA members have invested billions of dollars in building the advanced manufacturing infrastructure and developing critical technological advances that will allow us to accelerate vaccine development, identify and rapidly advance promising treatment options and quickly manufacture new vaccines and treatments for patients.

**RESEARCHING AND DEVELOPING POTENTIAL TREATMENTS**

Across PhRMA's membership, companies are scrutinizing inventories of existing research portfolio libraries of experimental medicines to identify additional potential treatments for investigation and emergency use. PhRMA members have also been manufacturing millions of doses of investigational and previously approved medicines that may have potential to treat coronavirus for emergency use and for use in clinical trials around the globe, including compounds formerly tested on other viral pathogens such as Ebola and HIV. These investigational treatments are designed to both stop the virus from attacking the body as well as to treat secondary conditions caused by the virus, such as bacterial infections.

**RESEARCHING AND DEVELOPING POTENTIAL VACCINES**

Vaccines train a person's immune system to recognize a pathogen such as COVID-19 and neutralize it before it can harm the body. Several members are researching vaccine candidates for prevention and collaborating to share existing technologies that can be leveraged to allow rapid upscale of production once successful vaccine candidates are identified.

Because the COVID-19 strand did not exist prior to December 2019, the vaccines in development for this specific strain of coronavirus are still in early phases of research. Vaccines generally need to undergo extensive clinical safety testing because they are intended for use in healthy people and must complete successful clinical trials before receiving regulatory approval. In the case of development of a COVID-19 vaccine, biopharmaceutical companies are using novel techniques to advance vaccine research at a faster pace than has ever been done before. Companies are working hard to progress early vaccine research in human clinical trials as soon as possible, and five vaccines are already in clinical trials. Companies are also using ingredients that act as an "adjuvant" that can boost the body's immune system response to the vaccine while requiring a smaller dose. This can help companies more quickly scale up production of vaccines once they are approved for use by the broader public.

Even with all these scientific advancements, companies and public health officials still predict it will likely take 12 to 18 months before the first vaccine is available.
THE BIOPHARMACEUTICAL INDUSTRY IS LEADING THE WAY IN DEVELOPING NEW VACCINES AND TREATMENTS FOR COVID-19

“We always need a pharmaceutical partner. I can’t think of a vaccine, even one in which we’ve put substantial intellectual and resource input, that was brought to the goal line without a partnership with industry. So this is a very natural process that we’re doing right now.... I have not seen in my experience situations in which we were involved in the development of a vaccine, particularly for low- and middle-income countries that really needed it, where the pharmaceutical companies priced it out of their reach.”

— NIAID Director Anthony Fauci (February 27, 2020)

MEDICINES AND VACCINES IN DEVELOPMENT FOR COVID-19

CLINICAL TRIALS
As of June 5, 2020, there are more than 1,100 clinical trials testing COVID-19 treatments and vaccines. Sponsors are trying a variety of approaches, including 1,080 clinical trials for COVID-19 treatments and over 30 clinical trials testing a vaccine, with about 250 of these clinical trials taking place in the United States. Some of the trials are being conducted in multiple countries simultaneously.

TREATMENTS
There are currently 363 unique treatments being tested globally for COVID-19 and COVID-19 related complications. The chart below shows the phases of development for current COVID-19 treatments. When analyzing the active clinical trials, of the 1,080 active clinical trials, a little more than half (55%) are targeting the virus directly, while the rest of the trials focus on related effects of COVID-19 such as pneumonia. Of the 1,080 active clinical trials, about 725 trials are testing medicines previously approved for another indication, such as hydroxychloroquine and antiviral combinations and nearly 145 trials are testing novel compounds.
THE BIOPHARMACEUTICAL INDUSTRY IS LEADING THE WAY IN DEVELOPING NEW VACCINES AND TREATMENTS FOR COVID-19

VACCINES

There are currently more than 32 clinical trials underway to test 11 vaccine candidates. There are a total 15 trials in Phase I, Phase II and Phase II/III that are collectively enrolling over 26,520 patients. There are also Phase 3 trials testing a previously approved vaccine, mostly in front-line workers, which is aiming to enroll another 33,500 patients. Additionally, there are almost 130 preclinical studies ongoing for vaccine candidates, with many looking to move on to Phase I human clinical trials in the spring and summer of this year.

COVID-19 Treatments in Development by Phase (as of June 5, 2020)

<table>
<thead>
<tr>
<th>Early clinical research</th>
<th>Phase I</th>
<th>Phase I/II</th>
<th>Phase II</th>
<th>Phase II/III</th>
<th>Phase III</th>
<th>Phase IV (Post Market Studies)</th>
</tr>
</thead>
<tbody>
<tr>
<td>30</td>
<td>37</td>
<td>30</td>
<td>159</td>
<td>51</td>
<td>80</td>
<td>51</td>
</tr>
</tbody>
</table>

Number of COVID-19 Vaccine and Treatment Trials by Class (as of June 5, 2020)

- Antiviral: 300
- Anti-inflammatory: 350
- Monoclonal antibodies: 200
- Convalescent Plasma: 150
- Cell Therapy: 100
- TB Vaccine: 50
- Recombinant Vector Vaccine: 50
- Genetic Materials (i.e., mRNA and DNA): 0
- Protein Vaccine: 0
BIOPHARMACEUTICAL INDUSTRIES’ LESSONS LEARNED FROM PAST PUBLIC HEALTH EMERGENCIES

The rapid pace at which researchers have been able to understand this novel strain of coronavirus and get medicines into human clinical trials is a testament to the lessons learned by the biopharmaceutical industry from past public health emergencies.

The biopharmaceutical industry is committed to developing solutions to address this global public health emergency just as it has in the past. PhRMA member companies not only bring decades of expertise in infectious diseases, including other strains of coronavirus, but bring the infrastructure and technologies to allow us to quickly advance potential vaccine and treatment candidates to clinical trials and have the manufacturing capabilities and expertise to allow for quick scale-up.

---

1Clinical trial data as of June 5, 2020
2Clinical trial data as of June 5, 2020. Note some clinical trials have unknown phase information, many clinical trials are testing the same treatment candidate.
3Analysis of publicly available databases such as clinicaltrials.gov, AdisInsights and the World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP) as of June 5, 2020.
4Treatments in development by phase as of June 5, 2020. Note – some medicines may be in two different phases at the same time.
5https://www.gilead.com/purpose/advancing-global-health/covid-19/about-remdesivir